BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
♫ Tuesday, April 16th, 2024MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.
See more here:
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement